Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04032093 · ClinicalTrials.gov registry record · Phase 2
A Phase 2B Placebo-controlled, Randomized Study OF A Respiratory Syncytial Virus (RSV) Vaccine IN Pregnant Women
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,153
- Enrollment target
NCT04032093 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 1,153 participants.
The verdict
NCT04032093, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,153 participants
- Enrollment target
Study Summary
This Phase 2b study will evaluate the safety, tolerability, and immunogenicity of an RSV vaccine in pregnant participants who receive either one of 2 dose levels of the vaccine, formulated with or without aluminum hydroxide, or placebo, and investigate safety and characteristics of antibodies in their infants.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL RSV vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,153 participants |
| Start Date | 2019-08-07 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04032093
The ClinicalTrials.gov registry entry for NCT04032093 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04032093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04032093 about?
NCT04032093 is a clinical study titled "A Phase 2B Placebo-controlled, Randomized Study OF A Respiratory Syncytial Virus (RSV) Vaccine IN Pregnant Women". This Phase 2b study will evaluate the safety, tolerability, and immunogenicity of an RSV vaccine in pregnant participants who receive either one of 2 dose levels of the vaccine, formulated with or without aluminum hydroxide, or placebo, and investigate safety and characteristics of antibodies in the...
What is the current status of trial NCT04032093?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,153 participants. The study started on 2019-08-07. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT04032093?
The interventions under investigation include: Placebo (BIOLOGICAL), RSV vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04032093?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.